Chlup Rudolf, Krejci Jan, O'Connell Mark, Sebestova Blanka, Plicka Robert, Jezova Lucie, Brozova Tereza, Doubravova Blanka, Zalesakova Hana, Durajkova Emilia, Vojtek Jiri, Bartek Josef
Department of Physiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Department of Internal Medicine II - Gastroenterology and Hepatology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Dec;159(4):527-34. doi: 10.5507/bp.2015.007. Epub 2015 Mar 1.
The aim of this pilot study was to acquire insight into the parameters of glycaemic control, especially, (1) the time delay (lag phase) between plasma and tissue glucose concentrations in relation to rise and fall in glucose levels and (2) the rate of glucose increase and decrease.
Four healthy people (HP), 4 people with type 1diabetes (DM1) and 4 with type 2 diabetes (DM2) underwent concurrent glucose measurements by means of (1) the continuous glucose monitoring system (CGMS-Medtronic), Medtronic-Minimed, CA, USA, calibrated by the glucometer Calla, Wellion, Austria, and, (2) the Beckman II analyser to measure glucose concentrations in venous plasma. Samples were taken on 4 consecutive days in the fasting state and 4 times after consumption of 50 g glucose. Carelink Personal, MS Excel, Maple and Mat lab were applied to plot the evolution of glucose concentration and analyse the results. The time difference between increase and decrease was calculated for HP, DM 1 and DM 2.
In DM1and DM2, glucose tolerance testing (GTT) resulted in slower transport of glucose into subcutaneous tissue than in HP where the lag phase lasted up to 12 min. The maximum increase/decrease rates in DM1 and DM2 vs HP were 0.25 vs < 0.1 mmol/L/min.
CGMS is shown to provide reliable plasma glucose concentrations provided the system is calibrated during a steady state. The analysis of glucose change rates improves understanding of metabolic processes better than standard GTT.
本初步研究的目的是深入了解血糖控制参数,特别是:(1)血浆与组织葡萄糖浓度之间在葡萄糖水平上升和下降方面的时间延迟(滞后阶段);(2)葡萄糖增加和减少的速率。
4名健康人(HP)、4名1型糖尿病患者(DM1)和4名2型糖尿病患者(DM2)通过以下方式同时进行葡萄糖测量:(1)使用连续葡萄糖监测系统(CGMS - 美敦力),美敦力 - 迷你迈德,加利福尼亚州,美国,由奥地利韦利昂的卡拉血糖仪校准;(2)使用贝克曼II分析仪测量静脉血浆中的葡萄糖浓度。在空腹状态下连续4天取样,并在摄入50克葡萄糖后取样4次。使用Carelink Personal、MS Excel、Maple和Mat lab绘制葡萄糖浓度变化图并分析结果。计算HP、DM1和DM2中葡萄糖增加和减少之间的时间差。
在DM1和DM2中,葡萄糖耐量试验(GTT)显示葡萄糖进入皮下组织的运输比HP慢,HP的滞后阶段长达12分钟。DM1和DM2与HP相比的最大增加/减少速率分别为0.25与<0.1毫摩尔/升/分钟。
结果表明,只要系统在稳态期间进行校准,CGMS就能提供可靠的血浆葡萄糖浓度。与标准GTT相比,分析葡萄糖变化率能更好地理解代谢过程。